Q2 2024 |
|
|
|
|
|
|
13F-NT |
8/9/2024, 04:47 PM |
Q1 2024 |
|
|
|
|
|
|
13F-NT |
5/3/2024, 04:39 PM |
Q4 2023 |
|
|
|
|
|
|
13F-NT |
2/2/2024, 04:47 PM |
Q3 2023 |
|
|
|
|
|
|
13F-NT |
11/3/2023, 04:44 PM |
Q2 2023 |
|
|
|
|
|
|
13F-NT |
8/4/2023, 04:41 PM |
Q1 2023 |
|
|
|
|
|
|
13F-NT |
5/5/2023, 05:01 PM |
Q4 2022 |
18 |
$304M |
|
-$103M |
-$103M |
PCVX, VRNA, VERA, HLVX, ACET
|
13F-HR |
2/10/2023, 03:28 PM |
Q3 2022 |
19 |
$292M |
+$4.92M |
|
+$4.92M |
PCVX, VERA, HLVX, ACET, VRNA
|
13F-HR |
11/10/2022, 03:48 PM |
Q2 2022 |
21 |
$312M |
+$19.9M |
-$14.7M |
+$5.25M |
PCVX, SRRA, VERA, ACET, HLVX
|
13F-HR |
8/15/2022, 06:30 AM |
Q1 2022 |
20 |
$352M |
+$18.9M |
|
+$18.9M |
PCVX, VERA, ACET, SRRA, JSPR
|
13F-HR |
5/16/2022, 07:00 AM |
Q4 2021 |
20 |
$413M |
+$8.72M |
|
+$8.72M |
PCVX, VERA, JSPR, EFTR, ACET
|
13F-HR |
2/16/2022, 10:26 AM |
Q3 2021 |
20 |
$441M |
+$126M |
-$1.73M |
+$124M |
PCVX, EFTR, JSPRXXXX, VERA, PHAT
|
13F-HR |
11/15/2021, 06:05 AM |
Q2 2021 |
19 |
$324M |
+$56.7M |
$0 |
+$56.7M |
PCVX, PHAT, VERA, SIENXXXX, RPHM
|
13F-HR |
8/16/2021, 06:30 AM |
Q1 2021 |
17 |
$290M |
+$22.9M |
$0 |
+$22.9M |
PCVX, PHAT, ACET, VRNA, SIENXXXX
|
13F-HR |
5/17/2021, 06:11 AM |
Q4 2020 |
15 |
$292M |
+$43.1M |
-$86.4K |
+$43M |
PCVX, PHAT, SLNO, VRNA, NCNA
|
13F-HR |
3/1/2021, 10:18 AM |
Q3 2020 |
17 |
$468M |
+$27.3M |
-$43.1M |
-$15.8M |
PCVX, PSNL, PHAT, SLNO, CRSP
|
13F-HR |
11/16/2020, 05:15 AM |
Q2 2020 |
15 |
$355M |
+$139M |
|
+$139M |
PCVX, PSNL, PHAT, CRSP, SLNO
|
13F-HR |
8/14/2020, 03:27 PM |
Q1 2020 |
16 |
$151M |
+$9.09M |
|
+$9.09M |
PSNL, PHAT, CRSP, SLNO, XCUR
|
13F-HR |
5/14/2020, 06:05 AM |
Q4 2019 |
16 |
$207M |
+$48.9M |
-$6.65M |
+$42.3M |
PSNL, PHAT, CRSP, SIENXXXX, SLNO
|
13F-HR |
2/14/2020, 05:05 AM |
Q3 2019 |
14 |
$158M |
+$15.8M |
-$24M |
-$8.2M |
PSNL, CRSP, XCUR, SIENXXXX, SLNO
|
13F-HR |
11/14/2019, 05:06 AM |
Q2 2019 |
13 |
$261M |
+$148M |
-$12.6M |
+$135M |
PSNL, CRSP, SIENXXXX, AVDR, SLNO
|
13F-HR |
8/14/2019, 06:09 AM |
Q1 2019 |
14 |
$112M |
+$13.4M |
-$4.61M |
+$8.79M |
CRSP, SIENXXXX, CHMA, SLNO, AVDR
|
13F-HR |
5/15/2019, 06:15 AM |
Q4 2018 |
16 |
$110M |
+$7.98M |
-$3M |
+$4.98M |
CRSP, SIENXXXX, VRNA, SLNO, CHMA
|
13F-HR |
2/14/2019, 05:16 AM |
Q3 2018 |
16 |
$168M |
+$11.3M |
-$6.72M |
+$4.55M |
CRSP, SIENXXXX, VRNA, PRTK, OBSVF
|
13F-HR |
11/14/2018, 05:15 AM |
Q2 2018 |
16 |
$175M |
+$7.22M |
-$38.2M |
-$31M |
CRSP, SIENXXXX, PRTK, OBSVF, GTXI
|
13F-HR |
8/14/2018, 07:00 AM |
Q1 2018 |
16 |
$161M |
+$2.98M |
-$14.3M |
-$11.3M |
CRSP, SIENXXXX, PRTK, GTXI, OBSVF
|
13F-HR |
5/15/2018, 06:08 AM |
Q4 2017 |
17 |
$138M |
|
-$4.12M |
-$4.12M |
CRSP, SIENXXXX, PRTK, CBAY, OBSVF
|
13F-HR |
2/14/2018, 05:10 AM |
Q3 2017 |
18 |
$144M |
+$8.61M |
-$15.4M |
-$6.78M |
CRSP, SIENXXXX, PRTK, CBAY, CHMA
|
13F-HR |
11/14/2017, 05:13 AM |
Q2 2017 |
16 |
$126M |
|
-$2.53M |
-$2.53M |
CRSP, PRTK, SIENXXXX, CBAY, CASC
|
13F-HR |
8/14/2017, 06:02 AM |
Q1 2017 |
17 |
$134M |
+$6.72M |
-$926K |
+$5.8M |
CRSP, PRTK, SIENXXXX, CBAY, CASC
|
13F-HR |
5/15/2017, 07:36 AM |
Q4 2016 |
16 |
$118M |
+$53.2M |
-$1.76M |
+$51.4M |
CRSP, PRTK, SIENXXXX, NOVNXXXX, CHMA
|
13F-HR |
2/14/2017, 05:04 AM |
Q3 2016 |
20 |
$104M |
+$4.8M |
-$232K |
+$4.56M |
SIENXXXX, PRTO, PRTK, CEMP, CHMA
|
13F-HR |
11/14/2016, 06:20 AM |
Q2 2016 |
20 |
$95.5M |
+$4.78M |
|
+$4.78M |
PRTK, PRTO, SIENXXXX, TBRA, CEMP
|
13F-HR |
8/12/2016, 06:03 AM |
Q1 2016 |
19 |
$108M |
+$256K |
|
+$256K |
PRTK, CHMA, PRTO, SIENXXXX, CEMP
|
13F-HR |
5/13/2016, 06:16 AM |
Q4 2015 |
18 |
$166M |
+$6.11M |
-$249K |
+$5.86M |
CHMA, PRTO, PRTK, SIENXXXX, CEMP
|
13F-HR |
2/16/2016, 06:22 AM |
Q3 2015 |
17 |
$171M |
+$46.1M |
-$1.25M |
+$44.8M |
CHMA, PRTO, PRTK, SIENXXXX, EVAR
|
13F-HR |
11/13/2015, 05:49 AM |
Q2 2015 |
15 |
$216M |
+$19M |
-$3.65M |
+$15.3M |
SIENXXXX, PRTO, PRTK, AMRN, EVAR
|
13F-HR |
8/14/2015, 06:47 AM |
Q1 2015 |
17 |
$235M |
+$1.02M |
-$40.6M |
-$39.6M |
SIENXXXX, PRTK, SUPN, DRNA, PRTO
|
13F-HR |
5/14/2015, 06:03 AM |
Q4 2014 |
16 |
$352M |
+$108M |
|
+$108M |
RNA, PRTK, SIENXXXX, PTLA, SUPN
|
13F-HR |
2/13/2015, 05:12 AM |
Q3 2014 |
13 |
$167M |
+$25.7M |
-$14.1M |
+$11.6M |
RNA, EVAR, SUPN, PTLA, DRNA
|
Restatement |
11/25/2014, 02:07 PM |
Q2 2014 |
12 |
$215M |
+$1.58M |
|
+$1.58M |
RNA, SUPN, PTLA, DRNA, AMRN
|
13F-HR |
8/14/2014, 06:53 AM |
Q1 2014 |
13 |
$181M |
+$36.3M |
|
+$36.3M |
RNA, DRNA, SUPN, PTLA, AMRN
|
13F-HR |
5/20/2014, 06:33 PM |
Q4 2013 |
11 |
$133M |
|
|
|
PTLA, RNA, SUPN, AMRN, CEMP
|
13F-HR |
2/14/2014, 07:47 AM |